Ainos (NASDAQ:AIMD) Upgraded by Wall Street Zen to “Hold” Rating

by · The Markets Daily

Wall Street Zen upgraded shares of Ainos (NASDAQ:AIMD – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday morning.

Ainos Stock Performance

Shares of Ainos stock opened at $3.49 on Friday. The firm’s fifty day simple moving average is $3.16 and its 200-day simple moving average is $2.86. The stock has a market capitalization of $16.26 million, a price-to-earnings ratio of -0.70 and a beta of 2.25. Ainos has a 12 month low of $2.00 and a 12 month high of $5.00. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.88 and a quick ratio of 2.61.

Ainos (NASDAQ:AIMD – Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.99) EPS for the quarter.

About Ainos

(Get Free Report)

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.

Featured Stories